Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhalable nano into micro dry powders for ivacaftor delivery: The role of mannitol and cysteamine as mucus-active agents.

International journal of pharmaceutics - 30 May 2020

Porsio Barbara, Lentini Laura, Ungaro Francesca, Di Leonardo Aldo, Quaglia Fabiana, Giammona Gaetano, Cavallaro Gennara

Abstract excerpt

In this paper the innovative approach of nano into micro dry powders (NiM) was applied to incorporate into mannitol or mannitol/cysteamine micromatrices ivacaftor-loaded nanoparticles for pulmonary delivery in CF. Nanoparticles composed by a mixture of two polyhydrohydroxyethtylaspartamide copolymers containing loaded with ivacaftor at 15.5% w/w were produced. The nanoparticles were incorporated into...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Inhalation
Share to Aminophenols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chloride Channel Agonists

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Mannitol

Share to Nanoparticles

Share to Quinolones

Share to Rats, Inbred F344

Source

Identifiers

PMID: 32272167
DOI: 10.1016/j.ijpharm.2020.119304

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhalable nano into micro dry powders for ivacaftor delivery: The role of mannitol and cysteamine as mucus-active agents.PMID 32272167Read ↗

Nanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systemsSemantic proximity Read ↗

Assisting PNA Transport Through Cystic Fibrosis Human Airway Epithelia With Biodegradable Hybrid Lipid-Polymer NanoparticlesSemantic proximity Read ↗

Site-Specific Microparticle Inhalation Therapy: A New Approach to Nasopharyngeal SymptomsSemantic proximity Read ↗

Intranasal and Pulmonary Lipid Nanoparticles for Gene Delivery: Turning Challenges into OpportunitiesSemantic proximity Read ↗

Advancements in Drug Delivery Systems from Chewable Tablets to NanomedicineSemantic proximity Read ↗

Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.Semantic proximity Read ↗

Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory SystemSemantic proximity Read ↗

Zwitterionic Inhaler with Synergistic Therapeutics for Reprogramming of M2 Macrophage to Pro-Inflammatory Phenotype.Semantic proximity Read ↗

Novel Dry Powder of Hyaluronic Acid-Vancomycin Complex for Inhalation Useful on Pulmonary Infections Associated to Cystic FibrosisSemantic proximity Read ↗

Unified Approaches in Modern Drug Delivery Covering Lipid Based Nanocarriers Controlled Release Mechanisms and Innovative Tablet TechnologiesSemantic proximity Read ↗

Novel Voriconazole-Loaded Hyalurosomes Optimized for Enhanced Skin Penetration and Antifungal Activity against Candida albicansSemantic proximity Read ↗

MicroRNA nanocarriers for the treatment of chronic obstructive pulmonary diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.